Imugene Launches Phase 1b Trial in Australia
Company Announcements

Imugene Launches Phase 1b Trial in Australia

Imugene Limited (AU:IMU) has released an update.

Imugene Limited has launched the first Australian site for its azer-cel Phase 1b clinical trial at the Royal Prince Alfred Hospital in Sydney, aiming to provide a new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This off-the-shelf CAR T-cell therapy uses donor T-cells, allowing for quicker treatment compared to traditional methods. Early results from U.S. trials have shown promising responses, offering hope to those with limited treatment options.

For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImugene Limited Begins Innovative Cancer Trial
TipRanks Australian Auto-Generated NewsdeskImugene Achieves Milestone in Cancer Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App